Construction Business Review Conferences
BIO Asia–Taiwan Exhibition 2026 takes place July 16–19 at TaiNEX 1, Taipei, Taiwan. Bringing together 22 countries, 900 companies, and 2,300 booths, it is one of Asia's leading biotechnology exhibitions.
The RNA Leaders program features scientific tracks covering in-depth development strategies, trends and technologies across the entire long and small RNA spectrum and areas of focus below RNA Leaders offers a variety of different social environments to enhance your networking opportunities and make the most of your presence this October.
RNA Therapeutics and Manufacturing Asia 2026 will bring together experts, researchers, and industry leaders to explore the latest trends in RNA therapeutics and manufacturing. Discussions will cover mRNA, RNA interference (RNAi), antisense oligonucleotides, scalable manufacturing solutions, optimizing RNA synthesis, purification, and quality control, while exploring cost-effective, high-yield production technologies. With Asia emerging as a key hub for RNA innovation, this conference offers a vital platform for professionals to share insights, tackle challenges, and drive the future of RNA-based therapies.
ChinaBio® Partnering Forum is the largest and most productive life science partnering event in China. To be held as a 2 days in-person, 2 days virtually, April 28–29, 2026, and May 6–7, 2026, the conference will bring together biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for four days of successful partnering.
Analytica Hanoi introduces the analytica brand to the capital city. As the official spinoff of analytica Vietnam, this inaugural exhibition is tailored to meet the specific needs of northern Vietnam’s fast-growing laboratory and analytical sectors. It provides a targeted platform for international and local companies to engage directly with key buyers, manufacturers, research institutions, and government representatives in the north. Bringing the strength and reputation of the analytica brand to Hanoi, the 2026 launch offers timely access to one of Vietnam’s most dynamic regional markets.
BIOCHINA 2026(11th) will be held from March 12–14 at the Suzhou International Expo Center. Following the success of BIOCHINA 2025 (10th), which welcomed 30,000 attendees in Suzhou, BIOCHINA continues its journey of boundless innovation and collaborative growth! Over the past decade, BIOCHINA has expanded from China's thriving biopharmaceutical sector to the world stage, establishing an international platform for industry connectivity and uniting global expertise to advance collaboration. Through technological breakthroughs, commercial implementation, capital support, and ecosystem integration, BIOCHINA has witnessed China's innovative drug industry evolve from following to leading, progressing alongside the industry and the times.
The RNA therapeutics industry is poised for a transformative 2025, driven by groundbreaking technological advancements, expanding clinical applications, and a rapidly growing pipeline of innovative therapies. Following the remarkable success of mRNA-based COVID-19 vaccines, the field has seen a surge in investment and research aimed at unlocking RNA's potential for a wide range of therapeutic uses. From targeted cancer treatments to ex vivo gene therapies for rare genetic disorders, the RNA therapeutics sector is experiencing exciting developments that continue to gain momentum.
Building on the success of its 6th edition, the 7th Vaccine World Asia Congress 2025 – South East Asia, emerges as the premier event for vaccine companies in the region. With the rising demand for vaccines to tackle diseases like dengue, hepatitis, and influenza, governments across Southeast Asia are prioritizing immunisation, driving significant investments in vaccine research, development, and distribution. Technological innovations, including mRNA vaccines and enhanced delivery systems, are revolutionizing the market, enabling more rapid and effective responses to health threats.
South East Asia vaccine market is rapidly emerging as a significant player within the global vaccine industry, driven by increased investments, technological advancements, and governmental support. Countries such as Thailand, Indonesia, Malaysia, the Philippines, and Vietnam are leading the charge, offering unique advantages for major pharmaceutical and biopharmaceutical companies, including robust research capabilities and favorable regulatory environments. As the industry continues to expand, the region is poised to deliver even more exciting developments in vaccines.
The 3rd Biologics Contract Manufacturing Asia 2024 is a premium event that focuses exclusively on Contract Manufacturing in Asia-Pacific. The conference addresses the growing market of contract manufacturing, the predicted trends in the market, challenges faced by CMOs/ CDMOs, as well as the solutions and opportunities moving forward.
